Detalles de la búsqueda
1.
Sustained response of galcanezumab in migraine prevention: Patient-level data from a post hoc analysis in patients with episodic or chronic migraine.
Headache
; 63(10): 1380-1390, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37132481
2.
Does "wearing off" of efficacy occur in galcanezumab-treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trials.
Headache
; 62(2): 198-207, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35076090
3.
A phase IV clinical trial of gastrointestinal motility in adult patients with migraine before and after initiation of a calcitonin gene-related peptide ligand (galcanezumab) or receptor (erenumab) antagonist.
Headache
; 62(9): 1164-1176, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36111429
4.
Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine.
Headache
; 60(10): 2304-2319, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-33249580
5.
Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine.
Brain
; 142(7): 1894-1904, 2019 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31132795
6.
Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study.
Neurology
; 91(24): e2222-e2232, 2018 12 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30446595
7.
Atomoxetine-Related Change in Sluggish Cognitive Tempo Is Partially Independent of Change in Attention-Deficit/Hyperactivity Disorder Inattentive Symptoms.
J Child Adolesc Psychopharmacol
; 27(1): 38-42, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27845858
8.
Effect of Atomoxetine Treatment on Reading and Phonological Skills in Children with Dyslexia or Attention-Deficit/Hyperactivity Disorder and Comorbid Dyslexia in a Randomized, Placebo-Controlled Trial.
J Child Adolesc Psychopharmacol
; 27(1): 19-28, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27410907
9.
Atomoxetine Increased Effect over Time in Adults with Attention-Deficit/Hyperactivity Disorder Treated for up to 6 Months: Pooled Analysis of Two Double-Blind, Placebo-Controlled, Randomized Trials.
CNS Neurosci Ther
; 22(7): 546-57, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-26922462
10.
Differential response profiles in children and adolescents with attention-deficit/hyperactivity disorder: treatment with atomoxetine.
Clin Pediatr (Phila)
; 54(2): 164-73, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25371450
11.
Reading outcomes of children and adolescents with attention-deficit/hyperactivity disorder and dyslexia following atomoxetine treatment.
J Child Adolesc Psychopharmacol
; 24(8): 419-25, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25299355
12.
Meta-analysis of suicide-related behavior or ideation in child, adolescent, and adult patients treated with atomoxetine.
J Child Adolesc Psychopharmacol
; 24(8): 426-34, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25019647
13.
Atomoxetine tolerability in pediatric and adult patients receiving different dosing strategies.
J Clin Psychiatry
; 74(12): 1217-23, 2013 Mar 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-24434090
14.
Atomoxetine improved attention in children and adolescents with attention-deficit/hyperactivity disorder and dyslexia in a 16 week, acute, randomized, double-blind trial.
J Child Adolesc Psychopharmacol
; 23(9): 605-13, 2013 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-24206099
15.
Atomoxetine once daily for 24 weeks in adults with attention-deficit/hyperactivity disorder (ADHD): impact of treatment on family functioning.
Clin Neuropharmacol
; 35(3): 125-33, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22561876
16.
Once-daily treatment with atomoxetine in adults with attention-deficit/hyperactivity disorder: a 24-week, randomized, double-blind, placebo-controlled trial.
Clin Neuropharmacol
; 34(2): 51-60, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-21406998
17.
Economic burden and comorbidities of attention-deficit/hyperactivity disorder among pediatric patients hospitalized in the United States.
Child Adolesc Psychiatry Ment Health
; 4: 31, 2010 Dec 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-21156063
18.
Effects of atomoxetine on self-reported high-risk behaviors and health-related quality of life in adolescents with ADHD.
Curr Med Res Opin
; 26(9): 2087-95, 2010 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-20642391
19.
Atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder.
J Child Adolesc Psychopharmacol
; 19(6): 719-30, 2009 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-20035590
20.
Atomoxetine for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children with ADHD and dyslexia.
Child Adolesc Psychiatry Ment Health
; 3: 40, 2009 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-20003507
Resultados
1 -
20
de 20
1
Próxima >
>>